



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

17 January 2022
EMA/19629/2022
EMA/H/C/000460

Public statement

Ytracis

Withdrawal of the marketing authorisation in the European Union

On 20 December 2021, the European Commission withdrew the marketing authorisation for Ytracis (yttrium (90Y) chloride) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, CIS BIO International, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Ytracis was granted marketing authorisation in the EU on 24 March 2003 for radiolabelling of carrier molecules. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2008. The product had not been marketed in the EU since 2021.

Ytracis is an identical product to Yttriga (yttrium (90Y) chloride), which is authorised in the EU to be used only for the radiolabelling of carrier molecules, which have been specifically developed and authorised for radiolabelling with this radionuclide.

The European Public Assessment Report (EPAR) for Ytracis will be updated to indicate that the marketing authorisation is no longer valid.

